Abstract
Background Type 2 diabetes (T2D) is a national health priority. Its rising prevalence is accompanied by a high burden of diabetes-related complications, many of which are preventable. Numerous glucose-lowering medications have been developed in recent years with growing evidence relating to their efficacy and safety. These advances have increased the complexity of prescribing decisions in T2D.
Original language | English |
---|---|
Pages (from-to) | 513-518 |
Number of pages | 6 |
Journal | Australian journal of general practice |
Volume | 51 |
Issue number | 7 |
DOIs | |
Publication status | Published - Jul 2022 |